Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2017
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2017
SUMMARY
According to the recently published report 'Tyrosine Protein Kinase Mer - Pipeline Review, H2 2017'; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 18 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.
The report 'Tyrosine Protein Kinase Mer - Pipeline Review, H2 2017' outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 12 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Glioblastoma Multiforme (GBM), Ovarian Cancer, Astrocytoma, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Esophageal Cancer, Gastric Cancer, Leukemias, Metastatic Colorectal Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinitis Pigmentosa (Retinitis) and Solid Tumor.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Tyrosine Protein Kinase Mer - Pipeline Review, H2 2017'; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 18 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.
The report 'Tyrosine Protein Kinase Mer - Pipeline Review, H2 2017' outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 12 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Glioblastoma Multiforme (GBM), Ovarian Cancer, Astrocytoma, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Esophageal Cancer, Gastric Cancer, Leukemias, Metastatic Colorectal Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinitis Pigmentosa (Retinitis) and Solid Tumor.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
- The report reviews Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Basilea Pharmaceutica Ltd
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Elsalys Biotech SAS
Ignyta Inc
Ono Pharmaceutical Co Ltd
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles
Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-196969 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-241161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-4501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit MERTK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOPE-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mer-590 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRX-2843 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRX-6313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mer Tyrosine Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MerTK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UNC-569 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2017: Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer Meeting
Oct 02, 2017: Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting
Apr 04, 2017: Ignyta Announces New Data Highlighting Broad Potential of RXDX-106 at the 2017 AACR Annual Meeting
Mar 28, 2017: Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting
Nov 29, 2016: Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting
Mar 21, 2016: New Kinase Inhibitor Effective against Drug-Resistant Leukemia, Preclinical Study Finds
Mar 11, 2013: Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
Jun 08, 2010: Graham’s Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs
Jun 08, 2010: Graham’s Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Basilea Pharmaceutica Ltd
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Elsalys Biotech SAS
Ignyta Inc
Ono Pharmaceutical Co Ltd
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles
Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-196969 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-241161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-4501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit MERTK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOPE-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mer-590 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRX-2843 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRX-6313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mer Tyrosine Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MerTK for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UNC-569 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2017: Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer Meeting
Oct 02, 2017: Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting
Apr 04, 2017: Ignyta Announces New Data Highlighting Broad Potential of RXDX-106 at the 2017 AACR Annual Meeting
Mar 28, 2017: Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting
Nov 29, 2016: Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting
Mar 21, 2016: New Kinase Inhibitor Effective against Drug-Resistant Leukemia, Preclinical Study Finds
Mar 11, 2013: Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
Jun 08, 2010: Graham’s Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs
Jun 08, 2010: Graham’s Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Pipeline by Celldex Therapeutics Inc, H2 2017
Pipeline by Celon Pharma SA, H2 2017
Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Pipeline by Elsalys Biotech SAS, H2 2017
Pipeline by Ignyta Inc, H2 2017
Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Pipeline by Qurient Co Ltd, H2 2017
Pipeline by Rigel Pharmaceuticals Inc, H2 2017
Pipeline by SignalChem Lifesciences Corp, H2 2017
Dormant Projects, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Pipeline by Celldex Therapeutics Inc, H2 2017
Pipeline by Celon Pharma SA, H2 2017
Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Pipeline by Elsalys Biotech SAS, H2 2017
Pipeline by Ignyta Inc, H2 2017
Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Pipeline by Qurient Co Ltd, H2 2017
Pipeline by Rigel Pharmaceuticals Inc, H2 2017
Pipeline by SignalChem Lifesciences Corp, H2 2017
Dormant Projects, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Basilea Pharmaceutica Ltd
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Elsalys Biotech SAS
Ignyta Inc
Ono Pharmaceutical Co Ltd
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Basilea Pharmaceutica Ltd
Celldex Therapeutics Inc
Celon Pharma SA
Dong-A Socio Holdings Co Ltd
Elsalys Biotech SAS
Ignyta Inc
Ono Pharmaceutical Co Ltd
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
